1887
  1. Home
  2. Eurosurveillance
  3. Volume 26, Issue 48, 02/Dec/2021
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

Until recently, children and adolescents were not eligible for COVID-19 vaccination. They may have been a considerable source of SARS-CoV-2 spread. We evaluated SARS-CoV-2 IgG antibody seroprevalence in Israeli children aged 0–15 years from January 2020 to March 2021. Seropositivity was 1.8–5.5 times higher than COVID-19 incidence rates based on PCR testing. We found that SARS-CoV-2 infection among children is more prevalent than previously thought and emphasise the importance of seroprevalence studies to accurately estimate exposure.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.48.2101040
2021-12-02
2024-12-26
/content/10.2807/1560-7917.ES.2021.26.48.2101040
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/48/eurosurv-26-48-3.html?itemId=/content/10.2807/1560-7917.ES.2021.26.48.2101040&mimeType=html&fmt=ahah

References

  1. Radtke T, Ulyte A, Puhan MA, Kriemler S. Long-term symptoms after SARS-CoV-2 infection in children and adolescents. JAMA. 2021;326(9):869.  https://doi.org/10.1001/jama.2021.11880  PMID: 34264266 
  2. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-31.  https://doi.org/10.1038/s41591-021-01292-y  PMID: 33692530 
  3. Zhu Y, Bloxham CJ, Hulme KD, Sinclair JE, Tong ZWM, Steele LE, et al. A meta-analysis on the role of children in severe acute respiratory syndrome coronavirus 2 in household transmission clusters. Clin Infect Dis. 2021;72(12):e1146-53.  https://doi.org/10.1093/cid/ciaa1825  PMID: 33283240 
  4. Almadhi MA, Abdulrahman A, Sharaf SA, AlSaad D, Stevenson NJ, Atkin SL, et al. The high prevalence of asymptomatic SARS-CoV-2 infection reveals the silent spread of COVID-19. Int J Infect Dis. 2021;105:656-61.  https://doi.org/10.1016/j.ijid.2021.02.100  PMID: 33647516 
  5. Isreal Ministry of Health. COVID-19 daily situation report. Ramat-Gan: Isreal Ministry of Health; 2021. [Accessed: 3 Nov 2021]. Available from: https://datadashboard.health.gov.il/COVID-19/general
  6. Bassal R, Cohen D, Green MS, Keinan-Boker L. The Israel national sera bank: methods, representativeness, and challenges. Int J Environ Res Public Health. 2021;18(5):2280.  https://doi.org/10.3390/ijerph18052280  PMID: 33668988 
  7. Israel Central Bureau of Statistics (CBS). Characterization and classification of local authorities by the socio-economic level of the population in 2015. Jerusalem: CBS; 2021. Available from: https://din-online.info/pdf/lst92e.pdf
  8. Indenbaum V, Koren R, Katz-Likvornik S, Yitzchaki M, Halpern O, Regev-Yochay G, et al. Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis. PLoS One. 2020;15(11):e0241164.  https://doi.org/10.1371/journal.pone.0241164  PMID: 33227020 
  9. Oved K, Olmer L, Shemer-Avni Y, Wolf T, Supino-Rosin L, Prajgrod G, et al. Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation. EClinicalMedicine. 2020;29:100651.  PMID: 33235985 
  10. Lustig Y, Sapir E, Regev-Yochay G, Cohen C, Fluss R, Olmer L, et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir Med. 2021;9(9):999-1009.  https://doi.org/10.1016/S2213-2600(21)00220-4  PMID: 34224675 
  11. United States Food and Drug Administration (FDA). Coronavirus (COVID-19) update: FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic. Silver Spring: FDA; 2021. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use
  12. European Medicine Agency (EMA). First COVID-19 vaccine approved for children aged 12 to 15 in EU. 2021. Amsterdam: EMA; 2021. Available from: https://www.ema.europa.eu/en/news/first-covid-19-vaccine-approved-children-aged-12-15-eu
  13. United States Food and Drug Administration (FDA). Vaccines and Related Biological Products Advisory Committee October 26, 2021 Meeting Announcement. Silver Spring: FDA; 2021. Available from: https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age
  14. European Medicine Agency (EMA). Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11. Amsterdam: EMA; 2021. Available from: https://www.ema.europa.eu/en/news/comirnaty-covid-19-vaccine-ema-recommends-approval-children-aged-5-11.
  15. Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, et al. Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis. PLoS One. 2021;16(6):e0252617.  https://doi.org/10.1371/journal.pone.0252617  PMID: 34161316 
  16. Brotons P, Launes C, Buetas E, Fumado V, Henares D, de Sevilla MF, et al. Susceptibility to severe acute respiratory syndrome coronavirus 2 infection among children and adults: a seroprevalence study of family households in the Barcelona Metropolitan Region, Spain. Clin Infect Dis. 2021;72(12):e970-7.  https://doi.org/10.1093/cid/ciaa1721  PMID: 33180914 
  17. Zalcberg S, Block SZ. COVID-19 Amongst the Ultra-Orthodox Population in Israel: An Inside Look into the Causes of the High Morbidity Rates. Contemp Jew. 2021;41(1):1-23.  https://doi.org/10.1007/s12397-021-09368-0  PMID: 34305203 
  18. Yang Y, Wang X, Du RH, Zhang W, Si HR, Zhu Y, et al. Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses. Emerg Microbes Infect. 2021;10(1):905-12.  https://doi.org/10.1080/22221751.2021.1919032  PMID: 33870851 
Under-diagnosis of SARS-CoV-2 infections among children aged 0–15 years, a nationwide seroprevalence study, Israel, January 2020 to March 2021
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Victoria+Indenbaum&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Indenbaum Victoria</a>, <a href="/search?value1=Yaniv+Lustig&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Lustig Yaniv</a>, <a href="/search?value1=Ella+Mendelson&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mendelson Ella</a>, <a href="/search?value1=Yael+Hershkovitz&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hershkovitz Yael</a>, <a href="/search?value1=Aharona+Glatman-Freedman&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Glatman-Freedman Aharona</a>, <a href="/search?value1=Lital+Keinan-Boker&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Keinan-Boker Lital</a>, <a href="/search?value1=Ravit+Bassal&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bassal Ravit</a></span>. Under-diagnosis of SARS-CoV-2 infections among children aged 0–15 years, a nationwide seroprevalence study, Israel, January 2020 to March 2021. <a href="/content/ecdc">Euro Surveill.</a> 2021;26(48):pii=2101040. <a href="https://doi.org/10.2807/1560-7917.ES.2021.26.48.2101040" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2021.26.48.2101040</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 10 Nov 2021;&nbsp;&nbsp; <span class="generated">Accepted</span>: 02 Dec 2021 </span> </p>
/content/10.2807/1560-7917.ES.2021.26.48.2101040
/content/10.2807/1560-7917.ES.2021.26.48.2101040
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error